Skip to main content
Download PDF

Antiplasmodial potential of isolated xanthones from Mesua ferrea Linn. roots: an in vitro and in silico molecular docking and pharmacokinetics study

BMC Complementary Medicine and Therapies volume 24, Article number: 282 (2024) Cite this article

Abstract

Background

Malaria is a major global health concern, particularly in tropical and subtropical countries. With growing resistance to first-line treatment with artemisinin, there is an urgent need to discover novel antimalarial drugs. Mesua ferrea Linn., a plant used in traditional medicine for various purposes, has previously been investigated by our research group for its cytotoxic properties. The objective of this study was to explore the compounds isolated from M. ferrea with regards to their potential antiplasmodial activity, their interaction with Plasmodium falciparum lactate dehydrogenase (PfLDH), a crucial enzyme for parasite survival, and their pharmacokinetic and toxicity profiles.

Methods

The isolated compounds were assessed for in vitro antiplasmodial activity against a multidrug-resistant strain of P. falciparum K1 using a parasite lactate dehydrogenase (pLDH) assay. In vitro cytotoxicity against Vero cells was determined using the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay. The interactions between the isolated compounds and the target enzyme PfLDH were investigated using molecular docking. Additionally, pharmacokinetic and toxicity properties were estimated using online web tools SwissADME and ProTox-II, respectively.

Results

Among the seven compounds isolated from M. ferrea roots, rheediachromenoxanthone (5), which belongs to the pyranoxanthone class, demonstrated good in vitro antiplasmodial activity, with the IC50 being 19.93 µM. Additionally, there was no toxicity towards Vero cells (CC50 = 112.34 µM) and a selectivity index (SI) of 5.64. Molecular docking analysis revealed that compound (5) exhibited a strong binding affinity of − 8.6 kcal/mol towards PfLDH and was stabilized by forming hydrogen bonds with key amino acid residues, including ASP53, TYR85, and GLU122. Pharmacokinetic predictions indicated that compound (5) possessed favorable drug-like properties and desired pharmacokinetic characteristics. These include high absorption in the gastrointestinal tract, classification as a non-substrate of permeability glycoprotein (P-gp), non-inhibition of CYP2C19, ease of synthesis, a high predicted LD50 value of 4,000 mg/kg, and importantly, non-hepatotoxic, non-carcinogenic, and non-cytotoxic effects.

Conclusions

This study demonstrated that compounds isolated from M. ferrea exhibit activity against P. falciparum. Rheediachromenoxanthone has significant potential as a scaffold for the development of potent antimalarial drugs.

Peer Review reports

Background

Malaria continues to be a global health issue affecting populations in many tropical and subtropical countries [1]. According to the World Malaria Report 2022, there were 247 million cases of malaria and 619,000 fatalities from the illness in 2021. The African region had the highest burden, accounting for approximately 95% of cases and 96% of global deaths [2]. Among the five Plasmodium species that cause malaria in humans, P. falciparum is the most lethal, accounting for over 90% of malaria-related fatalities worldwide [3].

In areas with endemic transmission, artemisinin-based combination therapies (ACTs) are recommended as first-line therapy for uncomplicated P. falciparum [4, 5]. ACTs involve a combination of artemisinin derivatives, which are fast-acting drugs capable of clearing most parasites within 3 days of treatment. These drugs are coupled with long-acting partner drugs to eliminate any remaining parasites [6]. Unfortunately, the emergence and spread of artemisinin resistance, particularly in the Greater Mekong Subregion (GMS), poses a serious threat to malaria control [7]. This resistance, characterized by delayed parasite clearance, has spread to other regions, including South America, Papua New Guinea, and Eastern Africa [8, 9]. Treatment efficacy heavily relies on the effectiveness of partner drugs, with resistance to drugs like mefloquine and piperaquine leading to high ACTs treatment failure rates [10, 11]. Therefore, the ongoing pursuit of novel antimalarial drugs remains an urgent priority for malaria control.

Medicinal plants play a crucial role in human well-being, serving as primary sources of medicines and reservoirs of phytochemicals that provide a foundation for the development of novel drugs [12]. Notably, 25% of new molecular entities (NMEs) approved by the Food and Drug Administration (FDA) are plant-based natural products [13]. Successful plant-derived antimalarial drugs include quinine, an alkaloid from Cinchona tree that serves as a scaffold for chloroquine synthesis, and artemisinin, a sesquiterpene lactone from Artemisia annua L. [14, 15]. Semi-synthetic derivatives of artemisinin, such as artesunate, dihydroartemisinin, and artemether, have been developed to improve bioavailability [16, 17]. The success of these plant-derived antimalarial drugs has led to the search for novel plant-based alternatives to address growing resistance to current treatments.

Mesua ferrea Linn., also known as Ceylon ironwood, belongs to the Calophyllaceae family. This tropical tree is distributed in most Southeast Asian countries, including India, Sri Lanka, and Thailand [18]. Whole plant parts of M. ferrea have been extensively utilized in traditional medicine for the treatment of various diseases. M. ferrea is traditionally used as a carminative, expectorant, diuretic, cardiotonic, antipyretic, and antimicrobial agent [19]. Several studies have demonstrated that phytochemicals derived from this plant possess a range of pharmacological properties, including antioxidant [20], anti-inflammatory [21], anti-microbial [22], antimalarial [23], anti-diabetic [24], anti-cancer [25], and immunomodulatory [19, 26]. Secondary metabolites isolated from Mesua species predominantly comprise xanthones and coumarins [27].

In a previous investigation, our research team effectively extracted bioactive xanthones from the roots of M. ferrea and investigated their cytotoxic effects against various cell lines, including A375 (human melanoma cells), PC-3 (human prostate cancer cells), and HaCaT (human keratinocyte immortal cells) [28]. However, to date, no further investigations have reported the antiplasmodial activity of compounds derived from M. ferrea roots. Therefore, the primary objective of the present study was to evaluate the antiplasmodial activities of selected xanthones isolated from M. ferrea roots. Furthermore, we also investigated their potential modes of action on the target Plasmodium falciparum lactate dehydrogenase (PfLDH) through molecular docking techniques and integrated in silico pharmacokinetics and toxicity properties (ADMET) predictions into our methodology.

Methods

Parasite culture and maintenance

The P. falciparum K1 strain, kindly donated by Dr. Rapatbhorn Patrapuvich of Mahidol University, Thailand, was cultured in accordance with Trager and Jensen’s method, with minor modifications [29]. Briefly, the process involved thawing the cryopreserved parasites in a sodium chloride solution, following which the thawed parasites were transferred to Roswell Park Memorial Institute 1640 medium (Gibco, Carlsbad, CA, USA). The culture medium was supplemented with human type O-positive erythrocytes, 2 mg/mL of sodium bicarbonate (Sigma-Aldrich, St. Louis, MO, USA), 4.8 mg/mL of HEPES (C8H18N2O4S) (HiMedia, Mumbai, India), 10 µg/mL of hypoxanthine (C5H4N4O) (Sigma-Aldrich, USA), 0.5% of AlbuMAX™ II (a lipid-rich bovine serum albumin) (Gibco, Auckland, New Zealand), and 2.5 µg/mL of gentamycin (Sigma-Aldrich, New Delhi, India). The cultured parasites were incubated at 37 °C in a 5% CO2 atmosphere following an established protocol [30]. The percentage of parasitemia was determined by preparing thin blood smears, stained with Giemsa (Biotechnical, Bangkok, Thailand), and examined under a light microscope with a 100X oil immersion objective lens (Olympus CX31, Model CX31RBSFA, Tokyo, Japan).

Extraction and isolation of compounds from M. ferrea

M. ferrea roots were collected from Trang province, Thailand (GPS coordinates: N7°18.781′, E99° 50.364′), and botanical identification was confirmed by an expert affiliated with the Forest Herbarium and assigned the voucher specimen number BKF 194350. Plant specimens were formally deposited at the Forest Herbarium and housed in the Department of National Parks, Wildlife, and Plant Conservation in Bangkok, Thailand.

In accordance with a previous study conducted by our research group, 8.3 kg of air-dried and pulverized M. ferrea L. root was sequentially extracted with 25 L of dichloromethane (CH2Cl2) and acetone solvents for a week at room temperature. The CH2Cl2 extract yielded 112.7 g of a yellow viscous residue, while the acetone extract yielded 25.0 g of a brownish residue. Seven compounds (1–7) were isolated from the CH2Cl2 and acetone extracts using chromatographic techniques. The compound structures were elucidated using spectroscopic methods [28]. Briefly, CH2Cl2 extract was subjected to quick column chromatography (QCC) on silica gel. Solvents with increasing polarities, n-hexane through ethyl acetate (EtOAc), were used for this purpose. The resulting eluates were combined into 12 fractions and subjected to thin-layer chromatography (TLC) analysis. Fraction 3 was subjected to column chromatography (CC) using an ethyl acetate (EtOAc)–hexane eluent (1:5, v/v), resulting in two compounds: 1-hydroxy-7-methoxyxanthone (1) and 1-hydroxy-5-methoxyxanthone (2). Subsequently, eight subfractions (3A–3H) were obtained from this fraction. Subfraction 3H was further separated by CC using CH2Cl2–hexane (3.5:1.5, v/v) as the eluent to isolate 1,6-dihydroxyxanthone (3). Fraction 4 was subjected to QCC using a solvent gradient from hexane to CH2Cl2 to methanol (MeOH). This process generated 12 sub-fractions (4A–4L). Compound (4), 1,5-dihydroxyxanthone, was isolated from subfraction 4C via recrystallization using EtOAc-hexane (1:4, v/v). Fraction 5 was subjected to QCC with an EtOAc-hexane gradient, yielding five subfractions (5A–5E). Subfraction 5C was further separated by CC, employing an CH2Cl2–hexane eluent (4:2, v/v), resulting in six subfractions (5C1–5C6). Subfraction 5C6 was subsequently purified by TLC using EtOAc–hexane (1:5, v/v) as the eluent, leading to the isolation of rheediachromenoxanthone (5). Fraction 7 was isolated using CC with a CH2Cl2–hexane eluent (4:2, v/v), yielding six subfractions (7A–7F). Subfraction 7E was further separated by CC, employing acetone–hexane elution (1:4, v/v), resulting in three subfractions (7E1–7E3). Sub-fraction 7E3 was subsequently purified by CC using EtOAc–hexane (1:4, v/v) as the elution solvent, leading to the isolation of 1,5-dihydroxy-3-methoxyxanthone (6). The acetone extract was purified using QCC with hexane as the eluent, and the polarity was gradually increased from acetone to MeOH, resulting in six fractions. Fraction 4 was further purified by CC with an EtOAc–hexane eluent (2:3, v/v), yielding five subfractions (4A–4E). Sub-fraction 4D was purified by CC using EtOAc–hexane (2:3, v/v), yielding 2,5-dihydroxy-1-methoxyxanthone (7).

The chemical structures of all compounds were determined using NMR spectroscopic techniques. This structural determination was further corroborated by comparison with the available literature. In the present study, these compounds (Fig. 1) were evaluated for their antiplasmodial properties and selectivity.

Fig. 1
figure 1

Chemical structure of compounds 1–7 isolated from M. ferrea L. roots

Full size image

In vitro antiplasmodial activity

The objective of this study was to evaluate the antiplasmodial activity of the crude extracts and pure compounds isolated from M. ferrea L. roots. A modified parasite lactate dehydrogenase (pLDH) assay originally developed by Makler et al. (1993) was used [31]. Test extracts and pure compounds were dissolved in dimethyl sulfoxide (DMSO) (Merck, Darmstadt, Germany) to prepare stock solutions. Subsequently, the stock solutions were diluted to different concentrations ranging from 0.78 to 100 µg/mL. Two antimalarial drugs, artesunate and chloroquine (Sigma-Aldrich, USA), served as positive controls. DMSO and non-infected erythrocytes were used as the negative and baseline controls, respectively. Briefly, the infected erythrocytes (2% parasitemia and 2% erythrocytes) were transferred to a 96-well culture plate. Thereafter, the test extracts and pure compounds were added to each well in triplicate for each concentration. The plates containing the test samples were incubated at 37 °C in a 5% CO2 atmosphere for 72 h. Following incubation, the plates were subjected to three freeze-thaw cycles at − 20 °C, and 37 °C, to ensure erythrocyte lysis. The 20 µL of lysed erythrocyte solutions were then transferred to a new 96-well culture plate containing 100 µL/well of Malstat reagent (Merck) and 20 µL/well of p-nitroblue tetrazolium/phenazine ethosulfate (NBT/PES) solution (Sigma-Aldrich). The mixture was then incubated in the dark for 1 h. The absorbance of the resulting reactions was measured at 650 nm in a microplate reader following an established protocol [30]. The half-maximal inhibitory concentration (IC50) was calculated via nonlinear regression curve analysis using GraphPad Prism 6 (GraphPad Software, La Jolla, CA, USA).

In vitro cytotoxicity assessment and selectivity index (SI)

The purpose of this study was to determine the cytotoxicity of crude extracts and pure compounds isolated from M. ferrea roots on Vero cells. The MTT assay was performed according to an established protocol [30]. Briefly, Vero cells were cultured in Dulbecco’s Modified Eagle Medium (Gibco, USA) supplemented with 10% fetal bovine serum (FBS) (Sigma-Aldrich, New Delhi, India). Vero cell suspensions were seeded onto 96-well culture plates at a density of 1 × 104 cells per well. The seeded culture plates were incubated at 37 °C in a 5% CO2 atmosphere for 24 h to facilitate cell attachment. Subsequently, the cultured cells were exposed to the test extracts and pure compounds in triplicate for each concentration. Doxorubicin (Sigma-Aldrich, India) was used as a positive control, whereas DMSO served as a negative control. All extracts and pure compounds were dissolved in DMSO and added to the medium at a final concentration of 0.5% DMSO. Plates containing the test samples were incubated at 37 °C in a 5% CO2 atmosphere for 48 h. Following incubation, the cell culture supernatant was discarded, and 50 µL of MTT solution (5 mg/mL) (Thermo Fisher Scientific, Oregon, USA) was added to each well. The test plates were then incubated at 37 °C in a 5% CO2 atmosphere for 2 h. Subsequently, the supernatant was discarded, and 100 µL/well of DMSO was added to induce cell lysis and dissolve the formazan crystals. To estimate the reactions, absorbance was measured at 560 nm in a microplate reader, and the background absorbance at 670 nm was subtracted. The 50% cytotoxic concentration (CC50) was calculated using nonlinear regression curve analysis using GraphPad Prism 6. In addition, the selectivity index (SI) used to assess the ratio between the cytotoxicity against Vero cells (CC50) and the antiplasmodial activity against P. falciparum (IC50) was calculated for each crude extract and pure compound with the following formula below [32].

$$\:\text{S}\text{e}\text{l}\text{e}\text{c}\text{t}\text{i}\text{v}\text{i}\text{t}\text{y}\:\text{i}\text{n}\text{d}\text{e}\text{x}\:\left(\text{S}\text{I}\right)\:=\:{\text{C}\text{C}}_{50}/{\text{I}\text{C}}_{50}$$

Molecular docking

Ligand preparation

The three-dimensional (3D) structures of the ligands were obtained from the PubChem database [33]. The ligands included in the study were 1-hydroxy-7-methoxyxanthone (1) (PubChem CID: 12214329), 1-hydroxy-5-methoxyxanthone (2) (PubChem CID: 86168207), 1,6-dihydroxyxanthone (3) (PubChem CID: 5493674), 1,5-dihydroxyxanthone (4) (PubChem CID: 5480299), rheediachromenoxanthone (5) (PubChem CID: 5488729), 1,5-dihydroxy-3-methoxyxanthone or Mesuaxanthone A (6) (PubChem CID: 5281651), 2,5-dihydroxy-1-methoxyxanthone (7) (PubChem CID: 10848779), artesunate (a standard antimalarial drug) (PubChem CID: 6917864), and chloroquine (a standard antimalarial drug) (PubChem CID: 2719).

To ensure stable ligand conformations, all the structures were subjected to geometry optimization and energy minimization. This was accomplished using conjugate gradient algorithms and a Universal Force Field [34], implemented using Avogadro software v. 1.2.0 [35]. Subsequently, Gasteiger charges were added, and nonpolar hydrogen atoms were merged using AutoDockTools (ADT) v. 1.5.7 [36], as described previously [37]. Finally, all ligands were saved in the Protein Data Bank (PDB) in Partial Charge (Q) and Atom Type (PDBQT) format.

Protein preparation

The X-ray crystallographic structure of the target protein PfLDH complexed with 1,4-dihydronicotinamide adenine dinucleotide (NADH) and oxamate (PDB ID: 1LDG) [38] was obtained from the Research Collaboratory for Structural Bioinformatics Protein Data Bank (RCSB PDB) [39]. The resolution of the PfLDH structure was determined to be 1.74 Å, which falls within the range of 1.5 to 2.5 Å for conducting high-quality molecular docking studies [40]. The PfLDH structure was determined for subsequent molecular docking studies using ADT. This involved several steps, including adding missing residues and polar hydrogen atoms, removing water molecules and co-crystallized ligands, including NADH and oxamate, to create the apo form of PfLDH, as described earlier [41]. The resulting PfLDH structure was saved in the PDBQT format.

Molecular docking analysis

The potential molecular binding modes of the compounds isolated from M. ferrea roots, along with the antimalarial drugs chloroquine and artesunate, with the target enzyme PfLDH were investigated using AutoDock Vina [42, 43]. Based on a previous study that identified amino acid residues that interact with NADH cofactors, including GLY29, MET30, ILE31, GLY32, ASP53, ILE54, TYR85, THR97, GLY99, PHE100, VAL138, ASN140, and HIS195, the active site of PfLDH was determined [44]. Accordingly, a grid box was generated by ADT to cover the active site of PfLDH, with the center coordinates set at center_x = 32 Å, center_y = 30 Å, and center_z = 32 Å, as described earlier [41, 45, 46]. Using ADT, the dimensions of the grid box were set to 26 × 26 × 26 Å3 for x, y, and z directions, with a grid spacing of 1.000 Å. Molecular docking simulations were performed using AutoDock Vina v. 1.1.2, with an exhaustiveness value of 24, while other parameters were maintained at their default settings. Compounds with a higher negative score indicated strong binding affinity and were selected as the most probable binding conformations [47]. To validate the docking protocol, the native ligand NADH was redocked into the active site of PfLDH using the parameters mentioned earlier. Successful validation required the resulting root mean square deviation (RMSD) between the redocked ligand and the experimentally co-crystallized ligand to be below 2.0 Å. This ensured the reliability of the docking protocol before applying these parameters to other ligands [48, 49]. In this study, the RMSD of the redocked ligand was determined to be 0.775 Å, meeting the acceptance criteria of less than 2.0 Å, thereby affirming the accuracy and reliability of the docking protocol. Hydrogen bonds and hydrophobic interactions between the ligand atoms and amino acid residues of PfLDH were identified using the Protein Ligand Interaction Profiler (PLIP) web tool, utilizing the default parameters [50, 51]. The protein-ligand complexes were rendered using the PyMOL molecular graphic system v. 2.5.2 (Schrödinger, LLC, New York, NY, USA).

In silico pharmacokinetic and toxicity (ADMET) properties

The assessment of ADMET parameters is a crucial step in the early stages of drug testing and development, as this aims to reduce late-stage attrition in drug discovery programs [52]. In this context, we evaluated the ADMET properties of the most promising compounds in molecular docking studies in comparison with the antimalarial drugs chloroquine and artesunate. Towards this, we employed two online web tools: SwissADME [53] and ProTox-II [54]. In this process, all compounds under investigation were converted into their canonical Simplified Molecular Input Line Entry System (SMILES) format and subsequently submitted to SwissADME and ProTox-II. SwissADME was used to predict the physicochemical, drug-likeness, and pharmacokinetic properties. This tool also provides valuable parameters, including bioavailability radar plots and the Brain Or IntestinaL EstimateD (BOILED-Egg) predictive model. The assessment of drug likeness based on Lipinski’s rule of five (RO5) was used to determine the feasibility of a compound as an oral drug by considering four physicochemical parameters, as described in a previous review [55]. The bioavailability radar plot provides an initial overview of drug likeness through graphical representation by considering the optimal ranges of six key physicochemical properties, as described in SwissADME [53]. Moreover, the BOILED-Egg predictive model offered valuable insights into two pivotal pharmacokinetic parameters: passive human gastrointestinal absorption (HIA) and blood-brain barrier (BBB) permeation. In addition, this model facilitates the prediction of whether a compound functions as a substrate or non-substrate of P-glycoprotein (P-gp), a member of the ATP-binding cassette transporter (ABC transporters) [53, 56]. The fact that cytochrome P450 (CYP) enzymes play a significant role in drug elimination through metabolic biotransformation is essential and needs to be noted [53]. The inhibition of CYP enzymes is a major contributor to pharmacokinetic-related drug-drug interactions (DDIs), potentially leading to undesirable adverse effects [53]. Thus, the evaluation of compounds with the potential to inhibit CYP enzymes is a crucial aspect of drug discovery. Moreover, SwissADME offers a synthetic accessibility score ranging from 1 (indicating very easy synthesis) to 10 (indicating very difficult synthesis). Additionally, we employed the ProTox-II web server to predict various toxicological parameters, including acute oral toxicity, organ toxicity (hepatotoxicity), and various toxicological endpoints, including carcinogenicity, immunotoxicity, mutagenicity, and cytotoxicity, of the investigated compounds. Based on the globally harmonized system of classification and labeling of chemicals (GHS) using the LD50 thresholds described in ProTox-II, acute oral toxicity prediction was expressed the median lethal dose (LD50) in mg/kg and classified into six toxicity classes (class 1, toxic; class 6, non-toxic) [54, 57].

Results

In vitro antiplasmodial activity

The in vitro antiplasmodial activity against P. falciparum K1 of crude extracts and pure compounds isolated from M. ferrea L. roots is shown in Table 1. Antiplasmodial activity of crude extracts derived from plants is classified as follows: high activity (IC50 < 10 µg/mL), moderate activity (IC50 11–50 µg/mL), low activity (IC50 51–100 µg/mL), and inactive (IC50 > 100 µg/mL) [58]. According to these classifications, the dichloromethane extract of M. ferrea root exhibited moderate activity against the P. falciparum K1 strain, with an IC50 value of 13.63 µg/mL, whereas the acetone extract with an IC50 value exceeding 100 µg/mL had inactive antiplasmodial activity (Table 1). Similarly, the antiplasmodial activity of pure compounds derived from natural products is classified as follows: potent activity (IC50 < 1 µM), good activity (IC50 1−20 µM), moderate activity (IC50 20−100 µM), low activity (IC50 100−200 µM), and inactive (IC50 > 200 µM) [59]. Based on this classification, among the seven compounds isolated from the roots, rheediachromenoxanthone (5) showed good antiplasmodial activity with an IC50 value of 19.93 µM, followed by 2,5-dihydroxy-1-methoxyxanthone (7), which exhibited moderate activity with an IC50 value of 46.30 µM. While 1,5-dihydroxyxanthone (4), 1-hydroxy-5-methoxyxanthone (2), and 1,5-dihydroxy-3-methoxyxanthone (6) exhibited low activity, with IC50 values of 106.98, 163.75, and 198.27 µM, respectively, Conversely, 1,6-dihydroxyxanthone (3) and 1-hydroxy-7-methoxyxanthone (1) displayed inactive activity, with IC50 values of 226.13 and 345.56 µM, respectively (Table 1).

In vitro cytotoxicity and SI values

The in vitro cytotoxicity against Vero cells of crude extracts and pure compounds isolated from M. ferrea L. roots is shown in Table 1. Crude extracts are classified as toxic to cells when the CC50 value is less than 30 µg/mL [60]. Similarly, pure compounds are considered toxic to cells when the CC50 value is less than 100 µM, respectively [61]. According to these classifications, the dichloromethane and acetone extracts exhibited non-toxic effects against Vero cells, with an CC50 value of 183.95 and > 800 µg/mL, respectively. Among the seven isolated compounds, (1), (3), (4), (5), (6), and (7) demonstrated non-toxic effects against Vero cells, with CC50 values of 195.85, 182.78, 416.65, 112.34, 210.16, and 587.85 µM, respectively. In contrast, compound (2) exhibited toxic effects with a CC50 value of 62.01 µM (Table 1). Regarding the SI value, a higher SI value indicates more selectivity against P. falciparum. An SI value lower than 2 suggests general cytotoxicity, rendering the compound unsuitable for further development as an antimalarial candidate [62]. Based on this criterion, the dichloromethane extract exhibited moderate in vitro antiplasmodial activity with an SI value greater than 2, indicating selectivity against P. falciparum over Vero cells. Among the isolated compounds, compounds (4), (5), and (7) exhibited good to low in vitro antiplasmodial activity with SI values of 3.89, 5.64, and 12.70, respectively, indicating selectivity against P. falciparum. In contrast, compounds (1), (2), (3), and (6) exhibited low to inactive in vitro antiplasmodial activity and SI values lower than 2, suggesting more selectivity towards Vero cells (Table 1).

Table 1 Antiplasmodial activity against the P. falciparum K1 strain and the cytotoxicity of crude extracts and compounds isolated from M. ferrea L. roots
Full size table

Molecular docking

A molecular docking study was performed to investigate the possible binding interactions between the compounds isolated from M. ferrea roots and the target protein, PfLDH. The binding affinities and specific amino acid residues of PfLDH involved in hydrogen bond and hydrophobic interactions with each compound are shown in Table 2. A high negative value of binding affinity indicates a strong interaction between the receptor and ligand. Among the seven compounds, rheediachromenoxanthone (5), of the pyranoxanthone class, demonstrated the highest binding affinity of − 8.6 kcal/mol. The complex of rheediachromenoxanthone and PfLDH was stabilized by three hydrogen bonds with amino acid residues, including ASP53 (2.2 Å), TYR85 (3.2 Å), and GLU122 (2.0 Å). In addition, the complex is stabilized by seven hydrophobic interactions with amino acid residues, including VAL26, PHE52, ILE54 (two interactions), ALA98, LYS118, and ILE119. The methyl group positioned on the pyran ring is responsible for the hydrophobic interactions with the amino acid residue LYS118 (Fig. 2a). Significantly, the compound structure exhibited a remarkable fit within the active site of PfLDH, resulting in the formation of hydrogen bonds between the two hydroxyl groups at C1 and C5 with the same amino acid residues crucial for cofactor enzyme (NADH) binding (Fig. 3). Remarkably, rheediachromenoxanthone exhibited good in vitro antiplasmodial activity (IC50 = 19.93 µM), which strongly correlates with its exceptional binding affinity. Followed by artesunate, the potent antimalarial drug, which demonstrated a binding affinity slightly lower than rheediachromenoxanthone, with a binding affinity − 8.0 kcal/mol. Artesunate is stabilized by strong seven hydrogen bonds with amino acid residues, including GLY29 (2.5 Å and 3.2 Å), MET30 (2.7 Å), ILE31 (1.8 Å), GLY32 (2.2 Å), THR97 (2.2 Å), and GLY99 (2.6 Å), and by four hydrophobic interactions with amino acid residues, including ILE54, VAL55, ALA98, and PHE100, respectively (Fig. 2c). While chloroquine, the antimalarial drug, demonstrated a weak interaction with PfLDH with a binding affinity − 7.2 kcal/mol. Chloroquine is stabilized by three hydrogen bonds with amino acid residues, including GLY29 (3.4 Å), ASP53 (2.4 Å), and ILE54 (3.0 Å), and by seven hydrophobic interactions with amino acid residues, including ILE31, ILE54 (two interactions), ALA98, THR101, and ILE119 (two interactions), respectively (Fig. 2b).

Table 2 Binding affinity and interacting amino acid residues of compounds isolated from M. ferrea L. roots with PfLDH
Full size table
Fig. 2
figure 2

Predicted best binding mode of compounds within the active site of PfLDH. The PfLDH enzyme structure is represented as a light blue cartoon, and the interacting residues as ball and stick models, each labeled with its respective heteroatoms. The compounds are represented as ball and stick models and labeled according to their heteroatom elements: orange for carbon (C), white for hydrogen (H), red for oxygen (O), blue for nitrogen (N), and green for chlorine (Cl). Yellow dashed lines represent hydrogen bonds formed between interacting residues and compounds, with the associated bond length specified in angstroms (Å). Gray dashed lines represent hydrophobic interactions between interacting amino acid residues and the compounds. The compound, rheediachromenoxanthone (a), chloroquine (b), and artesunate (c)

Full size image
Fig. 3
figure 3

Superimposition of the best docked poses of rheediachromenoxanthone (orange), chloroquine (cyan), artesunate (magenta), and NADH (green) interacting with amino acid residues within the active site of PfLDH. The yellow dashed lines represent the hydrogen bonds

Full size image

In addition, 2,5-dihydroxy-1-methoxyxanthone (7) exhibited moderate in vitro antiplasmodial activity (IC50 = 46.30 µM) and a binding affinity of − 7.4 kcal/mol. Compound (7) was stabilized by two hydrogen bonds with amino acid residues ASP53 and TYR85 and by four hydrophobic interactions with amino acid residues PHE52, ILE54, ALA98, and ILE119 (Table 2). While, 1,5-dihydroxyxanthone (4) exhibited low in vitro antiplasmodial activity (IC50 = 106.98 µM) and a binding affinity of − 7.7 kcal/mol. Compound (4) was stabilized by two hydrogen bonds with amino acid residues ILE54 and GLU122 and by four hydrophobic interactions with amino acid residues VAL26, PHE52, ILE54, and ALA98 (Table 2). These findings are consistent with those observed for 1-hydroxy-5-methoxyxanthone (2) (IC50 = 163.75 µM) and 1,5-dihydroxy-3-methoxyxanthone (6) (IC50 = 198.27 µM). Compound (2) demonstrated a binding affinity of − 7.6 kcal/mol and was stabilized by only one hydrogen bond with the amino acid residue GLU122 and by four hydrophobic interactions with amino acid residues PHE52, ILE54, ALA98, and ILE119 (Table 2). Compound (6) demonstrated a binding affinity of − 7.5 kcal/mol and was stabilized by two hydrogen bonds with the amino acid residue ASP53 and ILE54 and by four hydrophobic interactions with amino acid residues VAL26, PHE52, ILE54, and ALA98 (Table 2). In particular, 1-hydroxy-7-methoxyxanthone (1), and 1,6-dihydroxyxanthone (3) displayed inactive in vitro antiplasmodial activities, with IC50 values of 345.56 and 226.13 µM, respectively. Compounds (1) and (3) demonstrated binding affinity of − 7.5 and − 7.6 kcal/mol, respectively (Table 2). Based on the molecular docking results presented in this study, it is evident that compounds (1), (2), (3), (4), (6), and (7) belonging to the simple oxygenated xanthone class exhibit slightly varying binding affinities, ranging from − 7.4 to − 7.7 kcal/mol. These binding affinities are in line with the observed in vitro antiplasmodial activity, which ranged from moderate to inactive. In contrast, rheediachromenoxanthone, classified as a pyranoxanthone, demonstrated the highest favorable binding affinity of − 8.6 kcal/mol, suggesting a strong propensity to effectively bind within the active site of PfLDH, a characteristic that strongly aligns with its good in vitro antiplasmodial activity. These results highlight the potential impact of structural distinctions on their respective antiplasmodial mechanisms.

In silico pharmacokinetic and toxicity (ADMET) properties

Based on the in vitro antiplasmodial activity and molecular docking, rheediachromenoxanthone was identified as the most promising compound. Consequently, this compound was selected for a further comprehensive investigation of its ADMET properties in comparison to the antimalarial drugs chloroquine and artesunate. The predicted physicochemical properties, drug-likeness, pharmacokinetic properties, and toxicity profiles of the investigated compounds are summarized in Table 3. The drug-likeness results demonstrated that none of the investigated compounds violated RO5, suggesting that all of them possess the potential to be considered for oral drugs (Table 3). The bioavailability radar considers six physicochemical parameters, with the pink areas representing the optimal ranges for each property. The results demonstrated that chloroquine and artesunate fell within the optimal range for all properties, thereby categorizing them as drug-like (Fig. 4b and c). Rheediachromenoxanthone demonstrated a slight deviation from the optimal range of saturation properties (fraction Csp3) (Fig. 4a). The BOILED-Egg predictive model revealed distinct patterns for the investigated compounds. Chloroquine was placed within the yellow region (yolk), indicating a high probability of BBB permeation. In contrast, rheediachromenoxanthone and artesunate were placed within the white region (albumin), indicating a pronounced likelihood of HIA. Furthermore, all compounds exhibited a non-substrate of P-gp (PGP–), indicating that they were not prone to efflux from either the central nervous system (CNS) or gastrointestinal tract (Fig. 5). The assessment of the inhibitory activity against the five major CYP isoforms by the investigated compounds revealed distinct patterns. Rheediachromenoxanthone inhibited CYP1A2, CYP2C9, CYP2D6, and CYP3A4, while chloroquine showed inhibitory activities against CYP1A2, CYP2D6, and CYP3A4. In contrast, artesunate did not inhibit any of the investigated CYP isoforms. Interestingly, none of the investigated compounds showed inhibitory activity against CYP2C19 (Table 3). The synthetic accessibility scores for rheediachromenoxanthone, chloroquine, and artesunate demonstrated varying degrees of ease of synthesis. Rheediachromenoxanthone, in particular, showed a low score of 3.57, implying relative ease of synthesis. Similarly, chloroquine had a low score of 2.76. In contrast, artesunate showed a notably higher score (6.67), indicating a significantly more complex and challenging synthetic procedure. In addition, the toxicity profiles, as determined through ProTox-II predictions, demonstrated that rheediachromenoxanthone was classified as toxicity class 5 for acute oral toxicity, with a predicted LD50 of 4,000 mg/kg. In contrast, chloroquine and artesunate were categorized as toxicity class 4 for acute oral toxicity, with predicted LD50 values of 750 mg/kg and 1,000 mg/kg, respectively. Moreover, all the investigated compounds showed no hepatotoxicity, carcinogenicity, or cytotoxicity. In contrast, all the investigated compounds exhibited immunogenicity. In addition, rheediachromenoxanthone and chloroquine exhibited active mutagenicity with prediction probabilities of 0.55 and 0.94, respectively (Table 3).

Table 3 Physicochemical properties, drug-likeness, pharmacokinetics properties, medicinal chemistry, and toxicity profiles of rheediachromenoxanthone, chloroquine, and artesunate
Full size table
Fig. 4
figure 4

Bioavailability radar plot for rheediachromenoxanthone (a), chloroquine (b), and artesunate (c). The pink area represents the optimal range for six physicochemical properties associated with oral bioavailability, and the red line represents the specific properties of each compound

Full size image
Fig. 5
figure 5

BOILED-Egg predictive model shows the placement of rheediachromenoxanthone, chloroquine, and artesunate. This model is conceptually grounded in two essential physicochemical properties: the WLOGP value, which reflects lipophilicity, and the TPSA value, which reflects polarity. The compound falling within the white region (albumin) represents a high probability of HIA absorption, while the compound falling within the yellow region (yolk) represents a high probability of BBB permeation. The compound falling within the gray region is unlikely to be absorbed through HIA or the BBB. The red dots represent the compound as the P-gp non-substrate (PGP-).

Full size image

Discussion

In this study, all seven compounds isolated from the roots of M. ferrea were identified as xanthones, which are phenolic compounds characterized by a planar dibenzo-γ-pyron scaffold. Benzene rings A and B joined together by an oxygen atom and a carbonyl group (ring C), form the basic scaffold of xanthone [63]. Xanthones have been isolated from various natural sources, including higher plants, lichens, and microorganisms. These compounds possess various pharmacological properties, including anti-inflammatory, antioxidant, antimicrobial, and anticancer activities [64]. The interactions between xanthones and diverse pharmacological targets depend on the substitutions present on the two benzene rings [65]. The xanthones isolated from Mesua species are classified as three main groups of natural xanthones, including simple oxygenated xanthones, prenylated and related xanthones, and bisxanthones [27].

We investigated the antiplasmodial activities of dichloromethane and acetone extracts and compounds isolated from the roots of M. ferrea against the P. falciparum K1 strain. Among the seven compounds, rheediachromenoxanthone (5) exhibited the most substantial antiplasmodial activity against P. falciparum K1, with an IC50 value of 19.93 µM. However, rheediachromenoxanthone (5) exhibited lower antiplasmodial potency, being approximately 62.3 and 6,643.3-fold less potent than chloroquine and artesunate, respectively. In contrast, the simple oxygenated xanthone 2,5-dihydroxy-1-methoxyxanthone (7) displayed an IC50 value of 46.30 µM. Rheediachromenoxanthone (5) possessed markedly superior antiplasmodial activity, being approximately 2.3 times more potent than 2,5-dihydroxy-1-methoxyxanthone (7). The remarkable antiplasmodial activity of rheediachromenoxanthone (5) can be attributed to its unique structural characteristics, including an additional linear dimethylpyran ring. Our findings are in accordance with a previous study, which demonstrated that caloxanthone C, a pyranoxanthone isolated from the root barks of Calophyllum caledonicum that contains an additional pyran ring, had enhanced antiplasmodial activity against the chloroquine-resistant strains of P. falciparum FcB1/Colombia with an IC50 value of 1.3 µg/mL, as compared to its derivative, 1,3,5-trihydroxyxanthones, which demonstrated a considerably higher IC50 value of 24.7 µg/mL [66]. Additionally, macluraxanthone, a pyranoxanthone isolated from the stem bark of Garcinia bancana Miq. that contains a linear dimethylpyran ring and dimethylallyl group, has shown potent antiplasmodial activity against chloroquine-sensitive strains of P. falciparum 3D7 with an IC50 value of 4.28 µM when compared to isojacareubin, which contains only an angular dimethylpyran ring and displayed a considerably higher IC50 value of 11.45 µM [67].

Simple oxygenated xanthones were also observed in the extracts of M. ferrea root. The results showed that 2,5-dihydroxy-1-methoxyxanthone (7), which substitutes with two hydroxyl groups at C2 and C5 and one methoxy group at C1, demonstrated moderate antiplasmodial activity with an IC50 value of 46.30 µM. In contrast, 1,5-dihydroxyxanthone (4), which substitutes two hydroxyl groups at C1 and C5, exhibited low antiplasmodial activity with an IC50 value of 106.98 µM. Furthermore, 1-hydroxy-5-methoxyxanthone (2), which substitutes with one hydroxyl group at C1 and one methoxy group at C5, had an IC50 value of 163.75 µM. Similarly, 1,5-dihydroxy-3-methoxyxanthone (6), which substitutes with two hydroxyl groups at C1 and C5 and one methoxy group at C3, exhibited an IC50 value of 198.27 µM. Conversely, 1,6-dihydroxyxanthone (3), which substitutes for two hydroxyl groups at C1 and C6, demonstrated inactive antiplasmodial activity with an IC50 value of 226.13 µM. Additionally, 1-hydroxy-7-methoxyxanthone (1), which substitutes with one hydroxyl group at C1 and one methoxy group at C7, demonstrated the lowest antiplasmodial activity with an IC50 value of 345.56 µM.

These results indicated that the position and number of hydroxyl groups in the simple oxygenated xanthone structure have a significant impact on their antiplasmodial activity. Compounds with two hydroxyl groups at specific positions, C2 and C5, tended to have enhanced antiplasmodial activity, whereas the presence of hydroxyl groups at C1 and C5 or C1 alone tended to reduce activity. However, the number and position of methoxy groups can have varying effects on antiplasmodial activity. Our findings are consistent with those of a previous study, which demonstrated that compound 2,3,4,5,6-pentahydroxyxanthone potently inhibited in vitro heme polymerization with an IC50 value of 1.2 µM. This observation was consistent with its in vitro antiplasmodial activity against the chloroquine-sensitive strain of P. falciparum D6, with an IC50 value of 0.4 µM. The study demonstrated that a high number of hydroxyl groups is advantageous for inhibitory activity. This underscores the significance of the hydroxyl groups at positions C4 and C5, as they play a pivotal role in interacting with heme carboxylate groups, consequently leading to the inhibition observed in the in vitro heme polymerization assay. Additionally, the same study found that 2,3,4,5,6-pentamethoxyxanthone displayed no in vitro antiplasmodial activity or heme polymerization [68]. In addition, previous study demonstrated the substitution of a methoxy group on xanthone structure did not significantly enhance antimalarial activity [69]. Another study demonstrated that the presence of a hydroxyl group at the periposition, specifically at C1 or C8, results in reduced antiplasmodial activity. For instance, 1,3,5-trihydroxyxanthone displayed inactivity against P. falciparum D6, with an IC50 value exceeding 60 µM [70]. Regarding the SI values, among the isolated compounds, rheediachromenoxanthone (5) exhibited an SI value greater than 2. This indicates good selectivity against P. falciparum compared to normal cells (Vero cells). Therefore, rheediachromenoxanthone (5) should be prioritized for further investigation and development as a potential antimalarial candidate.

Structure-based drug design (SBDD) is an integral component of computer-aided drug design (CADD). Several drugs, such as captopril (Bristol Myers Squibb), saquinavir (Roche), zanamivir (Biota), and imatinib (Novartis), have successfully reached the market through the application of the SBDD technique [71]. Among the various SBDD techniques, molecular docking is the most widely used, primarily because of its capacity to facilitate a comprehensive understanding and prediction of molecular recognition interactions between small molecules and target macromolecules [72].

PfLDH serves as the terminal enzyme in the glycolytic pathway and is responsible for converting pyruvate to lactate using NADH as a cofactor. Among the LDH enzymes in human Plasmodium species (P. vivax, P. malariae, and P. ovale), in comparison to PfLDH, the sequence identity ranges from 90 to 92% [44]. A previous study revealed that the frequency of amino acid substitutions in global PfLDH populations is low, ranging from 0.3 to 3.3%. This observation suggests that the genetic polymorphism in PfLDH is well conserved, making it a promising candidate for drug development [73]. Furthermore, PfLDH exhibited a distinctive structural feature absent in human lactate dehydrogenase (hLDH), with the insertion of five amino acid residues within substrate-specific loops [74]. Additionally, PfLDH demonstrates distinct enzyme kinetic properties compared with hLDH [44, 75]. Ideally, antimicrobial molecular targets are selected based on their complete absence from human hosts [76]. In line with this principle, we selected PfLDH as the target owing to its distinctive structural and kinetic attributes relative to hLDH. The inhibition of PfLDH reduces ATP production, ultimately leading to the killing of the parasite [77]. Previous studies have shown that the azole-based compounds inhibit PfLDH activity, correlating with their efficacy against both chloroquine-sensitive and chloroquine-resistant P. falciparum (whole cells) [78]. For these reasons, several studies have proposed PfLDH as a promising molecular target for the development of novel antimalarial agents [38, 44, 77].

Molecular docking showed that rheediachromenoxanthone (5) exhibited the highest binding affinity towards PfLDH, with a binding affinity of − 8.6 kcal/mol. This high binding affinity is correlated with its good in vitro antiplasmodial activity, as evidenced by an IC50 value of 19.93 µM. In contrast, six simple oxygenated xanthones displayed binding affinities with PfLDH ranging from − 7.4 to − 7.7 kcal/mol, which correlated with their in vitro antiplasmodial activities varying from moderate to inactive. Notably, hydroxyl groups present in the xanthone structure play a crucial role in forming hydrogen bonds with the amino acid residues within the active site of PfLDH.

Chloroquine being previously identified as a weak inhibitor of PfLDH [79]. From our results, chloroquine interacts with PfLDH by forming three hydrogen bonds involving amino acid residues GLY29, ASP53, and ILE54. This observation aligns with a previous study that identified chloroquine binding to ASP53 and GLY99 of PfLDH [80]. Additionally, the quinoline ring of chloroquine occupied a position similar to that of the adenine ring of the NADH cofactor, which is consistent with earlier studies that identified chloroquine as a competitive inhibitor of the NADH cofactor [44, 81].

Artesunate is currently used as a first-line treatment for P. falciparum. The mechanism of activation of artemisinin and its derivatives involves cleavage of the endoperoxide bridge by either ferrous iron or heme, a byproduct of hemoglobin degradation in the digestive vacuole of parasites. This cleavage process generates carbon-centered radicals that can alkylate several essential proteins within the parasite [82]. In this study, artesunate exhibited a strong interaction with PfLDH with a binding affinity of − 8.0 kcal/mol compared to chloroquine. Previous studies have verified that PfLDH is a key enzyme susceptible to covalent modification by the bulk of activated artemisinin, leading to the irreversible disruption of its enzymatic activity [83].

According to the docking results, ASP53, ILE54, TYR85, and GLU122 are crucial amino acid residues within the PfLDH active site responsible for the interactions formed by hydrogen bonds with the isolated xanthone compounds. Our findings are similar to those of previous studies. The results demonstrated that compound 2, a derivative of 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine, formed five hydrogen bonds with the amino acid residues within the active site of PfLDH. These interactions involve ILE31, GLY32, ASP53, TYR85, and THR97. Remarkably, this binding pattern correlated with a high suppression of parasitemia, with a 99.09% suppression observed at a dose of 125 mg/kg body weight in Peter’s test [45]. In addition, synthetic quinoline-based compounds form hydrogen bonds with the amino acid residues within the active site of PfLDH. These interactions involve ASP53, ILE54, and GLY99 [84]. Moreover, previous studies demonstrated that the DAQ compound (chloroquine analog) exhibited potent antimalarial activity in both in vitro and in vivo models, consistent with the in silico prediction that the DAQ exhibited favorable interaction with PfLDH at the NADH binding site [81]. In line with these findings, our study demonstrated that rheediachromenoxanthone (5) exhibited good in vitro antiplasmodial activity and favorable interaction with specific amino acid residues within the active site of PfLDH, including ASP53, TYR85, and GLU122. These compelling results strongly support the selection of rheediachromenoxanthone (5) for further development as a novel inhibitor targeted at PfLDH. The molecular dynamics studies can be employed for further stability studies.

Regarding the other molecular targets of significant importance in the development of novel antimalarial drugs, such as P. falciparum dihydrofolate reductase-thymidylate synthase (PfDHFR-TS), as a crucial molecular target for designing antifolate antimalarial drugs, inhibition of this enzyme reduces the production of deoxythymidine monophosphate (dTMP) and DNA base synthesis [85]. The cytochrome bc1 complex (Complex III) is a crucial enzyme in the electron transport chain of P. falciparum, which also helps with the reoxidation of ubiquinol, which is necessary for ubiquinone-dependent dihydroorotate dehydrogenase (DHODH), an enzyme essential for pyrimidine biosynthesis [86, 87]. Inhibition of this enzyme by a known antimalarial drug (atovaquone) disrupts the mitochondrial membrane potential (ΔΨm), leading to parasite death [88]. Moreover, DHODH is the fourth enzyme in the pyrimidine biosynthesis pathway and is essential for parasite survival because parasites cannot salvage pyrimidines [86]. The novel antimalarial agent triazolopyrimidine, DSM265, which targets DHODH, has successfully entered clinical trial [89].

ADMET properties serve as critical factors in explaining how candidate compounds achieve appropriate concentrations at the therapeutic site of action while simultaneously maintaining a safe profile [90]. The in silico ADMET prediction is a particularly efficient and cost-effective approach for initial screening of candidate compounds before proceeding to an expensive clinical trial phase [91]. Our study revealed that rheediachromenoxanthone (5) did not violate RO5, indicating its favorable drug-like properties. Additionally, it shows a high likelihood of HIA, comparable to chloroquine and artesunate. Drugs intended for non-CNS indications should avoid BBB permeation to prevent potential adverse effects on the CNS [92]. Our findings demonstrated that only chloroquine exhibited BBB permeability, which has previously been reported to possibly cause adverse effects such as headache, dizziness, vomiting, and psychosis [93]. In contrast, neither rheediachromenoxanthone (5) nor artesunate permeated the BBB, suggesting a lower risk of CNS-related adverse effects. All compounds were non-substrate for P-gp, suggesting that these compounds are prone to low efflux, enhancing their potential therapeutic efficacy. Rheediachromenoxanthone (5) inhibited several CYP enzymes but not CYP2C19, suggesting a lower likelihood of DDIs or associated adverse effects. The synthetic accessibility of compounds significantly affects drug design, particularly due to the challenges posed by the synthesis of certain compounds [94]. Rheediachromenoxanthone showed a low synthetic accessibility score, indicating ease of synthesis, thereby enabling the potential for its large-scale production. Toxicological assessment demonstrated that rheediachromenoxanthone (5) had minimal acute oral toxicity with a high predicted LD50 value. In addition, rheediachromenoxanthone (5) exhibited non-hepatotoxic, non-carcinogenic, and non-cytotoxic properties, enhancing its safety profile.

Conclusions

Rheediachromenoxanthone, a pyranoxanthone compound isolated from the roots of M. ferrea L., exhibits good in vitro antiplasmodial activity while maintaining its non-toxicity towards normal cells (Vero cells). In addition, this compound exhibited a strong affinity for PfLDH, favorable drug-like properties, good pharmacokinetic properties, ease of synthesis, and low toxicity. Based on our findings, rheediachromenoxanthone shows high potential for use as a scaffold in the design of novel antimalarial drugs targeting PfLDH. Nevertheless, it is imperative to validate the potential of rheediachromenoxanthone through additional experimental investigations. These studies should include a medicinal chemistry-based approach to chemically modify the rheediachromenoxanthone scaffold to improve its antiplasmodial activities and pharmacokinetic properties. Furthermore, in vivo model studies are essential for a comprehensive validation of both the antimalarial efficacy and safety profiles. These efforts will advance the potential of rheediachromenoxanthone as a clinically effective antimalarial drug.

Data availability

No datasets were generated or analysed during the current study.

Abbreviations

ACTs:

Artemisinin-based combination therapies

ADMET:

Absorption, Distribution, Metabolism, Excretion, and Toxicity

ADT:

AutoDockTools

ATP:

Adenosine triphosphate

BBB:

Blood-brain barrier

CADD:

Computer-aided drug design

CC:

Column chromatography

CC50 :

The 50% cytotoxic concentration

CNS:

Central nervous system

CYP:

Cytochromes P450

DDIs:

Drug-drug interactions

DHODH:

Dihydroorotate dehydrogenase

DMSO:

Dimethyl sulfoxide

DNA:

Deoxyribonucleic acid

dTMP:

Deoxythymidine monophosphate

FBS:

Fetal bovine serum

GHS:

Globally harmonized system of classification and labeling of chemicals

GMS:

Greater Mekong Subregion

HBA:

Hydrogen bond acceptors

HBD:

Hydrogen bond donors

HIA:

Human gastrointestinal absorption

hLDH:

Human lactate dehydrogenase

IC50 :

The half maximal inhibitory concentration

LD50 :

Median lethal dose

NADH:

1,4-Dihydronicotinamide adenine dinucleotide

P-gp:

Permeability glycoprotein

PDB:

Protein Data Bank

PDBQT:

Protein Data Bank, Partial Charge (Q), and Atom Type format

PfDHFR-TS:

Plasmodium falciparum dihydrofolate reductase-thymidylate synthase

PfLDH:

Plasmodium falciparum lactate dehydrogenase

pLDH:

parasite lactate dehydrogenase

PLIP:

Protein Ligand Interaction Profiler

QCC:

Quick column chromatography

RMSD:

Root Mean Square Deviation

RO5:

Lipinski’s rule of five

SBDD:

Structure-based drug design

SMILES:

Simplified Molecular Input Line Entry System format

TLC:

Thin-layer chromatography

TPSA:

Topological polar surface area

References

  1. Weiland AS. Recent advances in imported malaria pathogenesis, diagnosis, and management. Curr Emerg Hosp Med Rep. 2023;11(2):49–57.

    Article  PubMed  PubMed Central  Google Scholar 

  2. WHO. World malaria report 2022. Geneva: World Health Organization; 2022.

    Google Scholar 

  3. Alemayehu A. Biology and epidemiology of Plasmodium falciparum and Plasmodium vivax gametocyte carriage: implication for malaria control and elimination. Parasite Epidemiol Control. 2023;21:e00295.

  4. Bennett A, Bisanzio D, Yukich JO, Mappin B, Fergus CA, Lynch M, Cibulskis RE, Bhatt S, Weiss DJ, Cameron E, et al. Population coverage of artemisinin-based combination treatment in children younger than 5 years with fever and Plasmodium falciparum infection in Africa, 2003–2015: a modelling study using data from national surveys. Lancet Glob Health. 2017;5(4):e418–27.

  5. Tindana P, Guissou R, Bolarinwa OA, Tou F, de Haan F, Dhorda M, Dondorp AM, Amaratunga C, Mokuolu OA, Ouedraogo JB, et al. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: an analysis of stakeholders’ perspectives in Burkina Faso and Nigeria. PLoS ONE. 2022;17(9):e0273249.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Uwimana A, Umulisa N, Venkatesan M, Svigel SS, Zhou Z, Munyaneza T, Habimana RM, Rucogoza A, Moriarty LF, Sandford R, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis. 2021;21(8):1120–8.

  7. Siddiqui FA, Liang X, Cui L. Plasmodium falciparum resistance to ACTs: emergence, mechanisms, and outlook. Int J Parasitol Drugs Drug Resist. 2021;16:102–18.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Ward KE, Fidock DA, Bridgford JL. Plasmodium falciparum resistance to artemisinin-based combination therapies. Curr Opin Microbiol. 2022;69:102193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Nguyen TD, Gao B, Amaratunga C, Dhorda M, Tran TN, White NJ, Dondorp AM, Boni MF, Aguas R. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies. Nat Commun. 2023;14(1):4568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Miotto O, Sekihara M, Tachibana SI, Yamauchi M, Pearson RD, Amato R, Gonçalves S, Mehra S, Noviyanti R, Marfurt J, et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog. 2020;16(12):e1009133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Uwimana A, Legrand E, Stokes BH, Ndikumana JM, Warsame M, Umulisa N, Ngamije D, Munyaneza T, Mazarati JB, Munguti K, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med. 2020;26(10):1602–8.

  12. Phumthum M, Balslev H, Barfod AS. Important medicinal plant families in Thailand. Front Pharmacol. 2019;10:1125.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Li FS, Weng JK. Demystifying traditional herbal medicine with modern approach. Nat Plants. 2017;3:17109.

    Article  PubMed  Google Scholar 

  14. Tajuddeen N, Van Heerden FR. Antiplasmodial natural products: an update. Malar J. 2019;18(1):404.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Ikram N, Simonsen HT. A review of biotechnological artemisinin production in plants. Front Plant Sci 2017, 8:1966.

  16. Paddon CJ, Keasling JD. Semi-synthetic artemisinin: a model for the use of synthetic biology in pharmaceutical development. Nat Rev Microbiol. 2014;12(5):355–67.

    Article  CAS  PubMed  Google Scholar 

  17. Eastman RT, Fidock DA. Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria. Nat Rev Microbiol. 2009;7(12):864–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  18. Manse Y, Sakamoto Y, Miyachi T, Nire M, Hashimoto Y, Chaipech S, Pongpiriyadacha Y, Morikawa T. Antiallergic properties of biflavonoids isolated from the flowers of Mesua ferrea Linn. Separations. 2022;9(5):127.

  19. Chahar MK, Sanjaya Kumar DS, Lokesh T, Manohara KP. In vivo antioxidant and immunomodulatory activity of mesuol isolated from Mesua ferrea L. seed oil. Int Immunopharmacol. 2012;13(4):386–91.

    Article  CAS  PubMed  Google Scholar 

  20. Rajesh KP, Manjunatha H, Krishna V, Kumara Swamy BE. Potential in vitro antioxidant and protective effects of Mesua ferrea Linn. Bark extracts on induced oxidative damage. Ind Crops Prod. 2013;47:186–98.

  21. Murthuza S, Manjunatha BK. In vitro and in vivo evaluation of anti-inflammatory potency of Mesua ferrea, Saraca asoca, Viscum album & Anthocephalus cadamba in murine macrophages raw 264.7 cell lines and Wistar albino rats. Beni Suef Univ J Basic Appl Sci. 2018;7(4):719–23.

    Google Scholar 

  22. Verotta L, Lovaglio E, Vidari G, Finzi PV, Neri MG, Raimondi A, Parapini S, Taramelli D, Riva A, Bombardelli E. 4-Alkyl- and 4-phenylcoumarins from Mesua ferrea as promising multidrug resistant antibacterials. Phytochemistry. 2004;65(21):2867–79.

  23. Chaniad P, Techarang T, Phuwajaroanpong A, Horata N, Septama AW, Punsawad C. Exploring potential antimalarial candidate from medicinal plants of Kheaw Hom remedy. Trop Med Infect Dis 2022, 7(11).

  24. Zhang D, Arunachalam K, Wang Y, Zhang Y, Yang J, Hein PP, Mon AM, Li J, Inta A, Yang X. Evaluation on antidiabetic properties of medicinal plants from Myanmar. ScientificWorldJournal 2021, 2021:1424675.

  25. Asif M, Yehya AHS, Dahham SS, Mohamed SK, Shafaei A, Ezzat MO, Abdul Majid AS, Oon CE, Abdul Majid AMS. Establishment of in vitro and in vivo anti-colon cancer efficacy of essential oils containing oleo-gum resin extract of Mesua ferrea. Biomed Pharmacother. 2019;109:1620–9.

    Article  CAS  PubMed  Google Scholar 

  26. Murthuza S, Manjunatha BK. Radioprotective and immunomodulatory effects of Mesua ferrea (Linn.) From western ghats of India., in irradiated Swiss albino mice and splenic lymphocytes. J Radiat Res Appl Sci. 2018;11(1):66–74.

    CAS  Google Scholar 

  27. Rouger C, Derbré S, Richomme P. Mesua sp.: chemical aspects and pharmacological relevance of prenylated polyphenols. Phytochem Rev. 2019;18(1):317–42.

    Article  CAS  Google Scholar 

  28. Chukaew A, Saithong S, Chusri S, Limsuwan S, Watanapokasin R, Voravuthikunchai SP, Chakthong S. Cytotoxic xanthones from the roots of Mesua ferrea L. Phytochemistry. 2019;157:64–70.

    Article  CAS  PubMed  Google Scholar 

  29. Trager W, Jensen JB. Human malaria parasites in continuous culture. 1976. J Parasitol 2005, 91(3):484–486.

  30. Phuwajaroanpong A, Chaniad P, Horata N, Muangchanburee S, Kaewdana K, Punsawad C. In vitro and in vivo antimalarial activities and toxicological assessment of Pogostemon cablin (Blanco) Benth. J Evid Based Integr Med. 2020;25:2515690x20978387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  31. Makler MT, Hinrichs DJ. Measurement of the lactate dehydrogenase activity of Plasmodium falciparum as an assessment of parasitemia. Am J Trop Med Hyg. 1993;48(2):205–10.

  32. Memvanga PB, Tona GL, Mesia GK, Lusakibanza MM, Cimanga RK. Antimalarial activity of medicinal plants from the Democratic Republic of Congo: a review. J Ethnopharmacol. 2015;169:76–98.

    Article  PubMed  Google Scholar 

  33. PubChem. 2023. (https://pubchem.ncbi.nlm.nih.gov/). Accessed on 10 July 2023. In.

  34. Rappe AK, Casewit CJ, Colwell KS, Goddard WA III, Skiff WM. UFF, a full periodic table force field for molecular mechanics and molecular dynamics simulations. J Am Chem Soc. 1992;114(25):10024–35.

    Article  CAS  Google Scholar 

  35. Hanwell MD, Curtis DE, Lonie DC, Vandermeersch T, Zurek E, Hutchison GR. Avogadro: an advanced semantic chemical editor, visualization, and analysis platform. J Cheminform. 2012;4(1):17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, Olson AJ. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30(16):2785–91.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Nwonuma CO, Balogun EA, Gyebi GA. Evaluation of antimalarial activity of ethanolic extract of Annona muricata L.: an in vivo and an in silico approach. J Evid Based Integr Med. 2023;28:2515690x231165104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Dunn CR, Banfield MJ, Barker JJ, Higham CW, Moreton KM, Turgut-Balik D, Brady RL, Holbrook JJ. The structure of lactate dehydrogenase from Plasmodium falciparum reveals a new target for anti-malarial design. Nat Struct Biol. 1996;3(11):912–5.

    Article  CAS  PubMed  Google Scholar 

  39. Research Collaboratory for Structural Bioinformatics Protein Data Bank. 2023. (https://www.rcsb.org/). Accessed on 10 July 2023. In.

  40. Khelfaoui H, Harkati D, Saleh BA. Molecular docking, molecular dynamics simulations and reactivity, studies on approved drugs library targeting ACE2 and SARS-CoV-2 binding with ACE2. J Biomol Struct Dyn. 2021;39(18):7246–62.

    Article  CAS  PubMed  Google Scholar 

  41. Chaniad P, Mungthin M, Payaka A, Viriyavejakul P, Punsawad C. Antimalarial properties and molecular docking analysis of compounds from Dioscorea bulbifera L. as new antimalarial agent candidates. BMC Complement Med Ther. 2021;21(1):144.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2010;31(2):455–61.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Eberhardt J, Santos-Martins D, Tillack AF, Forli S. AutoDock Vina 1.2.0: new docking methods, expanded force field, and python bindings. J Chem Inf Model. 2021;61(8):3891–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Penna-Coutinho J, Cortopassi WA, Oliveira AA, França TC, Krettli AU. Antimalarial activity of potential inhibitors of Plasmodium falciparum lactate dehydrogenase enzyme selected by docking studies. PLoS ONE. 2011;6(7):e21237.

  45. Tahghighi A, Mohamadi-Zarch S-M, Rahimi H, Marashiyan M, Maleki-Ravasan N, Eslamifar A. In silico and in vivo anti-malarial investigation on 1-(heteroaryl)-2-((5-nitroheteroaryl)methylene) hydrazine derivatives. Malar J 2020, 19(1):231.

  46. Chaniad P, Chukaew A, Payaka A, Phuwajaroanpong A, Techarang T, Plirat W, Punsawad C. Antimalarial potential of compounds isolated from Mammea siamensis T. Anders. flowers: in vitro and molecular docking studies. BMC Complement Med Ther. 2022;22(1):266.

  47. Xue Q, Liu X, Russell P, Li J, Pan W, Fu J, Zhang A. Evaluation of the binding performance of flavonoids to estrogen receptor alpha by Autodock, Autodock Vina and Surflex-dock. Ecotoxicol Environ Saf. 2022;233:113323.

    Article  CAS  PubMed  Google Scholar 

  48. Plewczynski D, Łaźniewski M, Augustyniak R, Ginalski K. Can we trust docking results? Evaluation of seven commonly used programs on PDBbind database. J Comput Chem. 2011;32(4):742–55.

    Article  CAS  PubMed  Google Scholar 

  49. Bell EW, Zhang Y. DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism. J Cheminform. 2019;11(1):40.

    Article  PubMed  PubMed Central  Google Scholar 

  50. Salentin S, Schreiber S, Haupt VJ, Adasme MF, Schroeder M. PLIP: fully automated protein-ligand interaction profiler. Nucleic Acids Res. 2015;43(W1):W443–447.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  51. Adasme MF, Linnemann KL, Bolz SN, Kaiser F, Salentin S, Haupt VJ, Schroeder M. PLIP 2021: expanding the scope of the protein-ligand interaction profiler to DNA and RNA. Nucleic Acids Res. 2021;49(W1):W530–4.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  52. Wishart DS. Improving early drug discovery through ADME modelling: an overview. Drugs R D. 2007;8(6):349–62.

    Article  CAS  PubMed  Google Scholar 

  53. Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Banerjee P, Eckert AO, Schrey AK, Preissner R. ProTox-II: a webserver for the prediction of toxicity of chemicals. Nucleic Acids Res. 2018;46(W1):W257–63.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  55. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001;46(1–3):3–26.

    Article  CAS  PubMed  Google Scholar 

  56. Daina A, Zoete V. A BOILED-Egg to predict gastrointestinal absorption and brain penetration of small molecules. ChemMedChem. 2016;11(11):1117–21.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  57. Drwal MN, Banerjee P, Dunkel M, Wettig MR, Preissner R. ProTox: a web server for the in silico prediction of rodent oral toxicity. Nucleic Acids Res 2014, 42(Web Server issue):W53–58.

  58. Kigondu EVM, Rukunga GM, Gathirwa JW, Irungu BN, Mwikwabe NM, Amalemba GM, Omar SA, Kirira PG. Antiplasmodial and cytotoxicity activities of some selected plants used by the Maasai community, Kenya. S Afr J Bot. 2011;77(3):725–9.

    Article  Google Scholar 

  59. Namukobe J, Kiremire BT, Byamukama R, Kasenene JM, Akala HM, Kamau E, Dumontet V. Antiplasmodial compounds from the stem bark of Neoboutonia macrocalyx pax. J Ethnopharmacol. 2015;162:317–22.

    Article  CAS  PubMed  Google Scholar 

  60. Odira HO, Mitema SO, Mapenay IM, Moriasi GA. Anti-inflammatory, analgesic, and cytotoxic effects of the phytexponent: a polyherbal formulation. J Evid Based Integr Med. 2022;27:2515690x221082986.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Černá L, Bildziukevich U, Rárová L, Trylčová J, Šaman D, Weber J, Lovecká P, Wimmer Z. Oxime derivatives of betulonic acid and platanic acid as novel cytotoxic or antiviral agents. React Chem Eng. 2024;9(5):1087–95.

    Article  Google Scholar 

  62. Koch A, Tamez P, Pezzuto J, Soejarto D. Evaluation of plants used for antimalarial treatment by the Maasai of Kenya. J Ethnopharmacol. 2005;101(1–3):95–9.

    Article  CAS  PubMed  Google Scholar 

  63. Remali J, Sahidin I, Aizat WM. Xanthone biosynthetic pathway in plants: a review. Front Plant Sci. 2022;13:809497.

    Article  PubMed  PubMed Central  Google Scholar 

  64. Yang C, Zhang L, Zhang W, Huang C, Zhu Y, Jiang X, Liu W, Zhao M, De BC, Zhang C. Biochemical and structural insights of multifunctional flavin-dependent monooxygenase FlsO1-catalyzed unexpected xanthone formation. Nat Commun. 2022;13(1):5386.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Na Y. Recent cancer drug development with xanthone structures. J Pharm Pharmacol. 2009;61(6):707–12.

    Article  CAS  PubMed  Google Scholar 

  66. Hay AE, Hélesbeux JJ, Duval O, Labaïed M, Grellier P, Richomme P. Antimalarial xanthones from Calophyllum caledonicum and Garcinia vieillardii. Life Sci. 2004;75(25):3077–85.

    Article  CAS  PubMed  Google Scholar 

  67. Rifaldi, Fadlan A, Fatmawati S, Purnomo AS, Ersam T. Antiplasmodial and anticancer activities of xanthones isolated from Garcinia bancana Miq. Nat Prod Res 2023:1–6.

  68. Ignatushchenko MV, Winter RW, Bächinger HP, Hinrichs DJ, Riscoe MK. Xanthones as antimalarial agents; studies of a possible mode of action. FEBS Lett. 1997;409(1):67–73.

    Article  CAS  PubMed  Google Scholar 

  69. Dua VK, Ojha VP, Roy R, Joshi BC, Valecha N, Devi CU, Bhatnagar MC, Sharma VP, Subbarao SK. Anti-malarial activity of some xanthones isolated from the roots of Andrographis paniculata. J Ethnopharmacol. 2004;95(2–3):247–51.

    Article  CAS  PubMed  Google Scholar 

  70. Ignatushchenko MV, Winter RW, Riscoe M. Xanthones as antimalarial agents: stage specificity. Am J Trop Med Hyg. 2000;62(1):77–81.

    Article  CAS  PubMed  Google Scholar 

  71. Zhu K-F, Yuan C, Du Y-M, Sun K-L, Zhang X-K, Vogel H, Jia X-D, Gao Y-Z, Zhang Q-F, Wang D-P, et al. Applications and prospects of cryo-EM in drug discovery. Mil Med Res. 2023;10(1):10.

    CAS  PubMed  PubMed Central  Google Scholar 

  72. Morris GM, Lim-Wilby M. Molecular docking. In: Molecular Modeling of Proteins edn. Edited by Kukol A. Totowa, NJ: Humana Press; 2008: 365–382.

  73. Lee J, Kim TI, Lê HG, Yoo WG, Kang J-M, Ahn S-K, Myint MK, Lin K, Kim T-S, Na B-K. Genetic diversity of Plasmodium vivax and Plasmodium falciparum lactate dehydrogenases in Myanmar isolates. Malar J. 2020;19(1):60.

  74. Choi SR, Pradhan A, Hammond NL, Chittiboyina AG, Tekwani BL, Avery MA. Design, synthesis, and biological evaluation of Plasmodium falciparum lactate dehydrogenase inhibitors. J Med Chem. 2007;50(16):3841–50.

  75. Brown WM, Yowell CA, Hoard A, Vander Jagt TA, Hunsaker LA, Deck LM, Royer RE, Piper RC, Dame JB, Makler MT, et al. Comparative structural analysis and kinetic properties of lactate dehydrogenases from the four species of human malarial parasites. Biochemistry. 2004;43(20):6219–29.

    Article  CAS  PubMed  Google Scholar 

  76. Winter VJ, Cameron A, Tranter R, Sessions RB, Brady RL. Crystal structure of Plasmodium berghei lactate dehydrogenase indicates the unique structural differences of these enzymes are shared across the Plasmodium genus. Mol Biochem Parasitol. 2003;131(1):1–10.

  77. Akinnusi PA, Olubode SO, Adebesin AO, Osadipe TJ, Nwankwo DO, Adebisi AD, Titilayo IB-A, Alo YM, Owoloye A, Oyebola KM. Structure-based scoring of anthocyanins and molecular modeling of PfLDH, PfDHODH, and PfDHFR reveal novel potential P. falciparum inhibitors. Inf Med Unlocked. 2023;38:101206.

    Article  Google Scholar 

  78. Cameron A, Read J, Tranter R, Winter VJ, Sessions RB, Brady RL, Vivas L, Easton A, Kendrick H, Croft SL, et al. Identification and activity of a series of azole-based compounds with lactate dehydrogenase-directed anti-malarial activity. J Biol Chem. 2004;279(30):31429–39.

    Article  CAS  PubMed  Google Scholar 

  79. Read JA, Wilkinson KW, Tranter R, Sessions RB, Brady RL. Chloroquine binds in the cofactor binding site of Plasmodium falciparum lactate dehydrogenase. J Biol Chem. 1999;274(15):10213–8.

  80. Alebachew Y, Bisrat D, Tadesse S, Asres K. In vivo anti-malarial activity of the hydroalcoholic extract of rhizomes of Kniphofia foliosa and its constituents. Malar J. 2021;20(1):3.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  81. Aguiar ACC, Murce E, Cortopassi WA, Pimentel AS, Almeida M, Barros DCS, Guedes JS, Meneghetti MR, Krettli AU. Chloroquine analogs as antimalarial candidates with potent in vitro and in vivo activity. Int J Parasitol Drugs Drug Resist. 2018;8(3):459–64.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Woodley CM, Amado PSM, Cristiano MLS, O’Neill PM. Artemisinin inspired synthetic endoperoxide drug candidates: design, synthesis, and mechanism of action studies. Med Res Rev. 2021;41(6):3062–95.

    Article  CAS  PubMed  Google Scholar 

  83. Wang J, Zhang CJ, Chia WN, Loh CC, Li Z, Lee YM, He Y, Yuan LX, Lim TK, Liu M, et al. Haem-activated promiscuous targeting of artemisinin in Plasmodium falciparum. Nat Commun. 2015;6:10111.

    Article  CAS  PubMed  Google Scholar 

  84. Singh R, Bhardwaj V, Purohit R. Identification of a novel binding mechanism of Quinoline based molecules with lactate dehydrogenase of Plasmodium falciparum. J Biomol Struct Dyn. 2021;39(1):348–56.

    Article  CAS  PubMed  Google Scholar 

  85. Yuvaniyama J, Chitnumsub P, Kamchonwongpaisan S, Vanichtanankul J, Sirawaraporn W, Taylor P, Walkinshaw MD, Yuthavong Y. Insights into antifolate resistance from malarial DHFR-TS structures. Nat Struct Biol. 2003;10(5):357–65.

    Article  CAS  PubMed  Google Scholar 

  86. Painter HJ, Morrisey JM, Mather MW, Vaidya AB. Specific role of mitochondrial electron transport in blood-stage Plasmodium falciparum. Nature. 2007;446(7131):88–91.

    Article  CAS  PubMed  Google Scholar 

  87. Vallières C, Fisher N, Meunier B. Reconstructing the Qo site of Plasmodium falciparum bc1 complex in the yeast enzyme. PLoS ONE. 2013;8(8):e71726.

    Article  PubMed  PubMed Central  Google Scholar 

  88. Barton V, Fisher N, Biagini GA, Ward SA, O’Neill PM. Inhibiting Plasmodium cytochrome bc1: a complex issue. Curr Opin Chem Biol. 2010;14(4):440–6.

    Article  CAS  PubMed  Google Scholar 

  89. Kokkonda S, Deng X, White KL, Coteron JM, Marco M, de las Heras L, White J, El Mazouni F, Tomchick DR, Manjalanagara K, et al. Tetrahydro-2-naphthyl and 2-Indanyl Triazolopyrimidines targeting Plasmodium falciparum dihydroorotate dehydrogenase display potent and selective antimalarial activity. J Med Chem. 2016;59(11):5416–31.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  90. Reichel A, Lienau P. Pharmacokinetics in drug discovery: An exposure-centred approach to optimising and predicting drug efficacy and safety. In: New Approaches to Drug Discovery edn. Edited by Nielsch U, Fuhrmann U, Jaroch S. Cham: Springer International Publishing; 2016: 235–260.

  91. Wang J, Hou T. Chap. 5 Recent Advances on in silico ADME Modeling. In: Annual Reports in Computational Chemistry. Volume 5, edn. Edited by Wheeler RA: Elsevier; 2009: 101–127.

  92. Hassan SSU, Zhang WD, Jin HZ, Basha SH, Priya S. In-silico anti-inflammatory potential of guaiane dimers from Xylopia vielana targeting COX-2. J Biomol Struct Dyn. 2022;40(1):484–98.

    Article  CAS  PubMed  Google Scholar 

  93. Chaudhry HE, Khan S, Jamil S, Shaik TA, Ehsan Ullah S, Bseiso A, Sathish M, Saleem F, Ghaffari MAZ. Chloroquine-induced psychosis: A case report. Cureus. 2022;14(10):e30498.

    PubMed  PubMed Central  Google Scholar 

  94. Fukunishi Y, Kurosawa T, Mikami Y, Nakamura H. Prediction of synthetic accessibility based on commercially available compound databases. J Chem Inf Model. 2014;54(12):3259–67.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The authors would like to express their profound gratitude to Professor Gudrun Ulrich-Merzenich from the Medical Clinic III, AG Synergy Research and Experimental Medicine, University Hospital Bonn, Germany, for kindly providing advice and invaluable comments during manuscript preparation. This research was supported by Walailak University Ph.D. Scholarships for High-Potential Candidates to Enroll in Doctoral Programs (Contract No. HP019/2021).

Funding

This project funded by the National Research Council of Thailand (NRCT) (Contact No. N41A670189) and the Walailak University Graduate Research Fund (Contract No. CGS-RF-2023/03). The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Author information

Authors and Affiliations

  1. College of Graduate Studies, Walailak University, Nakhon Si Thammarat, 80160, Thailand

    Atthaphon Konyanee, Arisara Phuwajaroanpong & Walaiporn Plirat

  2. School of Medicine, Walailak University, Nakhon Si Thammarat, 80160, Thailand

    Prapaporn Chaniad & Chuchard Punsawad

  3. Research Center in Tropical Pathobiology, Walailak University, Nakhon Si Thammarat, 80160, Thailand

    Atthaphon Konyanee, Prapaporn Chaniad, Arisara Phuwajaroanpong, Walaiporn Plirat & Chuchard Punsawad

  4. Chemistry Department, Faculty of Science and Technology, Suratthani Rajabhat University, Surat Thani, 84100, Thailand

    Arnon Chukaew

  5. School of Science, Walailak University, Nakhon Si Thammarat, 80160, Thailand

    Apirak Payaka

  6. Research Center for Pharmaceutical Ingredient and Traditional Medicine, Cibinong Science Center, National Research and Innovation Agency (BRIN), West Java, 16915, Indonesia

    Abdi Wira Septama

Authors
  1. Atthaphon Konyanee
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prapaporn Chaniad
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Arnon Chukaew
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Apirak Payaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Abdi Wira Septama
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Arisara Phuwajaroanpong
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Walaiporn Plirat
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Chuchard Punsawad
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceptualization, A.K., P.C., and C.P.; methodology, A.K., P.C., A.C., A.P., A.P., W.P., and C.P.; formal analysis, A.K., P.C., and C.P.; investigation, A.K., P.C., A.C., A.P., A.P., W.P., and C.P.; resource, P.C. and C.P.; data curation, A.K., P.C., A.W.S., and C.P.; original—draft preparation, A.K.; writing—review and editing, P.C., and C.P.; review and editing, A.W.S.; visualization, A.K., P.C., and C.P.; supervision, P.C., and C.P.; project administration, C.P.; funding acquisition, A.K. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Chuchard Punsawad.

Ethics declarations

Ethics approval and consent to participate

All the procedures conducted in research involving human participants adhered to the guidelines and regulations of the Declaration of Helsinki. The study was approved by the Human Research Ethics Committee of Walailak University (approval number WUEC-23-062-01). Prior to the collection of blood specimens for cultivation of P. falciparum strains, written informed consent was obtained from all participants. This study was approved by the Institutional Biosafety Committee of Walailak University. This approval signifies full compliance with the biosafety guidelines for modern biotechnology and the Pathogen and Toxin Act, B.E. 2015, under approval number WU-IBC-66-007.

Consent for publication

Not applicable.

Competing interests

The authors declare no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic supplementary material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Konyanee, A., Chaniad, P., Chukaew, A. et al. Antiplasmodial potential of isolated xanthones from Mesua ferrea Linn. roots: an in vitro and in silico molecular docking and pharmacokinetics study. BMC Complement Med Ther 24, 282 (2024). https://doi.org/10.1186/s12906-024-04580-5

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12906-024-04580-5

Keywords

BMC Complementary Medicine and Therapies

ISSN: 2662-7671

Contact us